ECP
ITCI

Elk Creek Partners’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Elk Creek Partners’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		$4.21M Buy
+274,034
New +$5.95M 0.72% 62

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $22.2B AUM 58.34% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Elk Creek Partners's ITCI Position: Q1 2020 in Review

Elk Creek Partners opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q1 2020: 274,034 shares worth $4.21M. The stake represents 0.72% of the portfolio and ranks #62 among its holdings.

139 funds tracked by Wall St. Rank hold ITCI as of Q1 2020.

  • Elk Creek Partners held 274,034 shares of Intra-Cellular Therapies Inc. worth $4.21M as of Q1 2020.
  • Intra-Cellular Therapies Inc. was a new Elk Creek Partners position in Q1 2020.
  • Intra-Cellular Therapies Inc. made up 0.72% of Elk Creek Partners's portfolio in Q1 2020, its #62 holding.
  • 139 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q1 2020.

Based on Elk Creek Partners's 13F filing for Q1 2020, filed 14 May 2020.